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Dear Editor:
Enterobacteriaceae are an important cause of infections,
and the infection recurred weeks after ﬁnishing the antibi-
otic cycle, which led to another hospitalisation. For this
reason, we decided to initiate treatment with the recent antibi-especially in immunocompromised patients. The recent
appearance of carbapenemase-producing enterobacteriaceae
otic ceftazidime–avibactam (C–A) for 2 weeks at a dose of
1000/250 mg  every 12 h, which achieved the deﬁnitive eradi-
ment of urinary infections and complicated intraabdominal
4has generated a real therapeutic challenge.1 Reported for the
ﬁrst time in the 1990s, in the last year we  have witnessed the
dissemination of these strains in several Spanish hospitals.
This has generated an important epidemiologic problem and
a challenging situation in immunosuppressed patients like
kidney transplant recipients.
We describe a case of recurring urinary infections due to
Klebsiella pneumoniae carbapenemase (KPC)-producing bacte-
ria in a 78-year-old male who had received a kidney transplant
in November 2013. His medical history included chronic kid-
ney disease secondary to membranous glomerulonephritis,
for which he had initiated haemodialysis in March 2013. As
a postoperative complication, he presented calyceal ﬁstula
that was refractory to 2 surgical procedures and was ﬁnally
repaired by endourologic injection of cyanoacrylate. The ﬁrst
hospitalisation was prolonged for more  than 2 months, dur-
ing which time he had several urinary infections secondary to
extended-spectrum beta-lactamase-producing Klebsiella pneu-
moniae, treated with meropenem. In successive controls, rectal
colonisation by KPC was observed. In the following months,
he was hospitalised 4 times for urinary infection secondary
to KPC, and possible urological causes were ruled out. Dif-
ferent antibiotic regimens were tried, including amikacin and
colistin, meropenem at high doses together with tigecycline,
as well as colistin and tigecycline. The duration of each of
these treatments lasted more  than 2 weeks while monitoring
the levels of those antibiotics that are more  nephrotoxic. The
urine cultures became negative, but this was only transitory
DOI of original article:
http://dx.doi.org/10.1016/j.nefro.2015.01.001.
 Please cite this article as: Caravaca-Fontán F, Jiménez-Álvaro S, M
Ceftazidima-avibactam en el tratamiento de infecciones urinarias p
Nefrologia. 2015;35:412–413.
∗ Corresponding author.
E-mail address: fcaravacaf@gmail.com (F. Caravaca-Fontán).cation of the urinary infection as well as the KPC carrier state.
Urinary tract infections are an important cause of mor-
bidity, hospitalisations and elevated hospital costs associated
with kidney transplantations. The most frequently involved
microorganisms are Gram-negative. The dissemination of
carbapenem-resistant strains has been associated with higher
mortality in transplanted patients.2,3 Prolonged hospitalisa-
tion and the previous use of carbapenems have been related
with a greater probability of developing these infections. In our
patient, the previous endourologic seal of the calyceal ﬁstula
with cyanoacrylate made us consider the possible correlation
that it may have had with the recurring infections, although
there is no evidence in the literature to support this.
This is the ﬁrst reported case of urinary infection due to
KPC in a renal transplant recipient cured with C-A. Avibac-
tam is a non-beta-lactam beta-lactamase inhibitor that, in
combination with ceftazidime, has demonstrated a bacteri-
cide effect in infections by resistant enterobacteriaceae and
those caused by Pseudomonas aeruginosa.1 Studies in animal
models have demonstrated that C–A is effective in menin-
gitis, septicaemia, pyelonephritis and pneumonia caused by
these strains. Currently, it is in phase 3 trial for the treat-arcén-Letosa R, Fernández-Rodríguez A, Rodríguez-Navarro CQ.
or Klebsiella productora de carbapenemasa en trasplante renal.
infections in humans. In our case, its administration was for
compassionate use, and it was shown to be a safe, effective
and well tolerated. Clinical trials are necessary to evaluate
the efﬁcacy of C–A, although the preliminary results look
promising.
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ear Editor:ur patient is a 70-year-old woman with chronic kidney
isease secondary to polycystic kidney disease. She began
aemodialysis in 1995 and received the ﬁrst deceased-donor
idney transplant (DDKT) in 1997; the graft was lost 15 days
ater due to acute rejection, followed by removal of the graft.
n 2004, a second DDKT was performed, and a kidney graft was
mplanted in the left iliac fossa with end-to-side anastomosis
f the external iliac artery with the renal artery; as induc-
ion immunosuppressive therapy, she received sequential
uadruple therapy with basiliximab, prednisone, mycophe-
olate mofetil and tacrolimus. The patient became stabilised
ith creatinine levels of 2 mg/dL. Her medical history also
ncluded type 2 diabetes mellitus, moderate-severe mitral
nsufﬁciency and severe peripheral arterial disease with bilat-
ral femoropopliteal obliteration diagnosed in 2007.
After kidney transplantation, blood pressure was con-
rolled with an -blocker until 5 months prior to the current
pisode, when she presented at ofﬁce visits with poor
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blood pressure (BP) control of 190/90 mmHg, Ambulatory
blood pressure monitoring (ABPM) showed a mean 24 h
BP of 166/89 mmHg  and a riser pattern despite treatment
with 3 drugs (-blocker, ß-blocker and diuretic). Treatment
with angiotensin-converting enzyme (ACE) inhibitors was
initiated, and 2 weeks later renal function decreased with
creatinine levels of 3.2 mg/dl; this drug was withdrawn and
renal function improved.
The patient reported symptoms that had been progressing
over a week period, including progressive dyspnoea, oedema
and a weight gain of 5 kg. Upon hospitalisation, she presented
a BP of 180/90 mmHg. Physical examination detected bibasilar
crackles, systolic murmur in the mitral area, absence of bilat-
eral dorsalis pedis pulses, pitting oedema and murmur in the
right groin. The workup upon admittance showed serum cre-
atinine 3.1 mg/dL; chest X ray presented signs of heart failure.
The oriented diagnosis was biventricular heart failure
in the context of a hypertensive crisis, and treatment was
initiated with nitro-glycerine and endovenous furosemide,
which resulted in improvement of both BP and heart failure.˜ o JF, Can˜as-Solé L, Bonet J, Lauzurica R. Obliteración de la arteria
ntado renal, un diagnóstico difícil y poco frecuente. Nefrologia.
